Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new...
HOOKIPA Pharma Inc. is a clinical stage biophar...
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global ...
Celgene Corporation, headquartered in Summit, N...
United-Guardian, Inc. ("United") is a diversified company that conducts research, ...
United-Guardian, Inc. ("United") is a diversifi...
The Medicines Company is a biopharmaceutical company driven by an overriding purpo...
The Medicines Company is a biopharmaceutical co...
UNITY Biotechnology is developing therapeutics to extend human healthspan by slowi...
UNITY Biotechnology is developing therapeutics ...
Sage Therapeutics is a biopharmaceutical company committed to developing novel the...
Sage Therapeutics is a biopharmaceutical compan...
Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...
Adaptimmune is a leader in TCR T-cell therapy, ...
We are a clinical-stage biopharmaceutical company committed to realizing the promi...
We are a clinical-stage biopharmaceutical compa...
Our strategy is to be known as âthe prostate cancer companyâ. We aspire to be ...
Our strategy is to be known as âthe prostate ...
We are a clinical-stage biopharmaceutical company focused on the development of no...
We are a clinical-stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.